<i>BRCA2</i>-<i>RB1</i> co-loss and ADT resistance in aggressive prostate cancer.
Goutam Chakraborty(National Centre for Cell Science), Philip W. Kantoff(Convergent Science (United States)), Kalyani Chadalavada(Memorial Sloan Kettering Cancer Center), Yuki Yoshikawa(Hiroshima Prefectural Hospital), Gwo‐Shu Mary Lee(Dana-Farber Cancer Institute), Ying Z. Mazzu(Memorial Sloan Kettering Cancer Center), Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), Konrad H. Stopsack(Memorial Sloan Kettering Cancer Center), Kazumasa Komura(Kawasaki Medical School), Nabeela Khan(Memorial Sloan Kettering Cancer Center), Mohammad Atiq(Memorial Sloan Kettering Cancer Center), Shin-Yi Du(Memorial Sloan Kettering Cancer Center), Joshua Armenia(AstraZeneca (United Kingdom))
Cited by 1
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Pan-cancer analysis of whole genomes
|Nature|2020|3.3k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k